Back
Axsome Therapeutics, Inc. Stock Predictions
Meet America's Newest $1B Unicorn
DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at
Buy
64
AXSM
Axsome Therapeutics, Inc.
Last Price:
$172.32
Seasonality Move:
-10.05%
7 Day Trial
ALL ACCESS PASS
$
7
The Next Gold Rush
DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available atAxsome Therapeutics, Inc. Stock Forecast
-
Over the next 52 weeks, Axsome Therapeutics, Inc. has on average historically risen by 107.8% based on the past 10 years of stock performance.
-
Axsome Therapeutics, Inc. has risen higher in 5 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
-
Is Axsome Therapeutics, Inc. Stock Undervalued?The current Axsome Therapeutics, Inc. [AXSM] share price is $167.55. The Score for AXSM is 64, which is 28% above its historic median score of 50, and infers lower risk than normal.
-
AXSM is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
Will Axsome Therapeutics, Inc. Stock Go Up Next Year?
-
Over the next 52 weeks, Axsome Therapeutics, Inc. has on average historically risen by 107.8% based on the past 10 years of stock performance.
Axsome Therapeutics, Inc. Stock Rating
Buy
64
Axsome Therapeutics, Inc. (AXSM)
is a Buy
Is Axsome Therapeutics, Inc. overpriced?
-
Axsome Therapeutics, Inc. has risen higher in 5 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
Axsome Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
axsome.com
52-Week Data
52-Week High:
184.40
52-Week Low:
79.19
Prediction Charts
Market Cap:
8.4B
Price in USD:
167.55
Volume:
808.9K
Beta:
1.53
Technical Analysis
SMA50:
147.60
SMA100:
134.27
SMA200:
120.58
52-Wk Change:
102.92%
Stock Predictions
-
Is Axsome Therapeutics, Inc. stock public?Yes, Axsome Therapeutics, Inc. is a publicly traded company.
-
What is the Axsome Therapeutics, Inc. stock quote today?The Axsome Therapeutics, Inc. stock price is 167.55 USD today.
-
How to buy Axsome Therapeutics, Inc. stock online?You can buy Axsome Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Dec-17 | 146.84 | 148.00 | 148.87 | 145.71 |
| Dec-18 | 148.19 | 147.00 | 149.00 | 145.88 |
| Dec-19 | 147.18 | 152.65 | 154.49 | 147.18 |
| Dec-22 | 152.65 | 154.70 | 156.39 | 152.65 |
| Dec-23 | 155.36 | 154.19 | 158.56 | 152.41 |
| Dec-24 | 154.74 | 153.64 | 155.84 | 153.50 |
| Dec-26 | 153.76 | 152.05 | 154.22 | 151.27 |
| Dec-29 | 152.00 | 150.68 | 153.15 | 150.01 |
| Dec-30 | 150.97 | 148.79 | 153.02 | 148.14 |
| Dec-31 | 158.49 | 182.64 | 184.40 | 158.49 |
| Jan-5 | 178.88 | 171.49 | 179.02 | 168.58 |
| Jan-6 | 173.00 | 171.88 | 176.00 | 170.30 |
| Jan-7 | 171.90 | 170.69 | 173.73 | 168.02 |
| Jan-8 | 168.97 | 167.55 | 170.59 | 165.75 |
Axsome Therapeutics, Inc. Earnings
Axsome Therapeutics, Inc. Earnings Report: Per Share Axsome Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.
Axsome Therapeutics, Inc. Forecast Revenue Growth
Axsome Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Axsome Therapeutics, Inc. and historical quarterly revenue growth:
-
Analysts estimate an earnings increase this quarter of $1.29 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.15 per share, and an increase next year of $6.04 per share.
* Axsome Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.